Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boryung Hepatitis A Vaccine in healthy children
NCT05613127Phase 3Unknown
- Sponsor
- Boryung Biopharma
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Boryung Hepatitis A Vaccine in hepatitis A (HAV) (2 arms), sponsored by Boryung Biopharma. Primary endpoint: Anti-HAV seroconversion rate. Status: unknown.
02
Drugs
Boryung Hepatitis A Vaccine
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT05613127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613127.